Stockreport

Sionna Therapeutics Reports Third Quarter 2025 Financial Results

Sionna Therapeutics, Inc.  (SION) 
PDF Initiated PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis Success [Read more]